SU - REGISTRATION REVIEW COMPLETE
registration review complete
on 03 Dec 2024
Last Applicant/ Owned by
2 Gansevoort Street, 9th Floor
New York
NY
10014
Serial Number
97715574 filed on 13th Dec 2022
Registration Number
N/A
Correspondent Address
Maury M. Tepper, III
Filing Basis
1. intent to use
2. use application currently
Disclaimer
NO DATA
BRIUMVI UBLITUXIMAB-XIIY 150 MG/6ML INJECTION FOR IV
pharmaceutical preparations for human use, namely, pharmaceutical preparations for the prevention and treatment of central nervous system disorders, multiple sclerosis, autoimmune diseases and B-cell mediated non-oncological diseases, the foregoing featuring monoclonal antibodies
Classification Information
Class [005]
Pharmaceutical Products
pharmaceutical preparations for human use, namely, pharmaceutical preparations for the prevention and treatment of central nervous system disorders, multiple sclerosis, autoimmune diseases and B-cell mediated non-oncological diseases, the foregoing featuring monoclonal antibodies
First Use Date in General
12th Jun 2023
First Use Date in Commerce
12th Jun 2023
Mark Details
Serial Number
No 97715574
Mark Type
No Service/Collective Mark
Attorney Docket Number
No
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Design Code(s)
26.19.01 -
Spheres
Legal History
| Status Date | Action Taken |
|---|---|
| 03rd Dec 2024 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| 03rd Dec 2024 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| 05th Nov 2024 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| 05th Nov 2024 | STATEMENT OF USE PROCESSING COMPLETE |
| 04th Sep 2024 | TEAS STATEMENT OF USE RECEIVED |
| 04th Sep 2024 | USE AMENDMENT FILED |
| 05th Mar 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 04th Mar 2024 | SOU EXTENSION 1 FILED |
| 04th Mar 2024 | SOU EXTENSION 1 GRANTED |
| 04th Mar 2024 | SOU TEAS EXTENSION RECEIVED |